Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 7, 2025Journal of Research in Pharmacy PracticeOpen Access

From Markup to Value: Global Implications of Iran’s Cost-plus Pharmaceutical Pricing for Emerging Markets

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHadi Hayat

Discussion

Loading...

Member takes

Overview

Comparative analysis shows cost-plus pricing inflates medicine prices in emerging markets, suggesting regulatory reforms.

Key Points

  • Iran's cost-plus pricing leads to a median price ratio (MPR) that is 178% higher compared to reference benchmarks.
  • Each 1% inflation increases the natural logarithm of MPR by 2%, indicating inflation's significant impact on medicine costs.
  • Phased reforms starting from CPI-indexed ceiling prices can reduce out-of-pocket expenses from 52% to 35%.
  • Adopting HTA-driven pricing models could potentially decrease out-of-pocket costs to 20%, improving healthcare affordability.

Cite This Study

Hadi Hayat (2025) studied this question.

synapsesocial.com/papers/68e585d0b1e78cc4e5f46417https://doi.org/10.4103/jrpp.jrpp_34_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12021 World Health Organization guideline on pharmacological treatment of hypertension: Policy implications for the region of the Americas2022 · 118 citations
  2. 2Availability, pricing and affordability of essential medicines in Eastern Ethiopia: a comprehensive analysis using WHO/HAI methodology2021 · 33 citations
  3. 3A desktop review of evaluation of implementation of national medicines policies in SADC countries2023 · 4 citations
  4. 4A systematic review of pharmaceutical pricing policies in developing countries2017 · 42 citations